Our study supports the importance of MYC as a potential target in AML, discovering its ability to reduce PP2A enzymatic activity through the regulation of SET transcription, and possibly CIP2A and SETBP1, defining a new layer of regulation that exists in the connection PP2A-MYC and SET-PP2A in cancer. This evidence concerns the gene MYC and acute myeloid leukemia.